Kiniksa Pharmaceuticals Corporation

BridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it

The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and f

The biopharmaceutical industry is in intense conflict over a case that could determine how broadly a patent can cover a cutting edge invention. More than a dozen companies have taken opposite sides in

Galderma S.A. ’s ongoing makeover continues with the skin care specialist revealing positive topline Phase III results in atopic dermatitis for nemolizumab. The first-in-class IL-31 receptor alpha inh